Gain Therapeutics (NASDAQ:GANX - Get Free Report) is expected to be releasing its earnings data before the market opens on Tuesday, March 25th. Analysts expect Gain Therapeutics to post earnings of ($0.19) per share for the quarter.
Gain Therapeutics Price Performance
Shares of GANX traded up $0.04 during mid-day trading on Friday, hitting $2.33. 111,929 shares of the stock were exchanged, compared to its average volume of 279,761. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. The company has a market cap of $61.67 million, a PE ratio of -2.14 and a beta of 0.14. Gain Therapeutics has a 52-week low of $0.89 and a 52-week high of $4.63. The firm has a 50-day moving average of $2.23 and a two-hundred day moving average of $2.01.
Analyst Ratings Changes
Several research firms have commented on GANX. Roth Mkm reiterated a "buy" rating and set a $7.00 price objective on shares of Gain Therapeutics in a research report on Tuesday, December 24th. HC Wainwright reaffirmed a "buy" rating and issued a $8.00 price target on shares of Gain Therapeutics in a report on Monday. Roth Capital upgraded Gain Therapeutics to a "strong-buy" rating in a research report on Thursday, December 5th. Finally, Scotiabank assumed coverage on Gain Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $12.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $8.20.
Read Our Latest Research Report on Gain Therapeutics
About Gain Therapeutics
(
Get Free Report)
Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.
Further Reading
Before you consider Gain Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gain Therapeutics wasn't on the list.
While Gain Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
